Markets

Biogen (BIIB) Beats on Q4 Earnings; Misses Sales

Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. The company is best known for its multiple sclerosis (MS) franchise comprising treatments like Avonex, Tysabri, Tecfidera and Plegridy.

Meanwhile, by Feb 1, 2017, Biogen will be spinning off its hemophilia business into a new company, Bioverativ. The spin-off will allow Biogen to focus on the neurology segment, its key area of expertise.

BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 8.15%.

Biogen Inc. Price and EPS Surprise

Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote

Currently, BIIB has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings Beat: BIIB's fourth quarter 2016 earnings were better-than expected. The company posted earnings of $5.04 per share while our consensus called for EPS of $4.97.

Revenues Miss: Biogen posted revenues of $2.87 billion, missing the consensus estimate of $2.95 billion.

Key Statistics: Oral multiple sclerosis (MS) drug Tecfidera's revenues declined 3% sequentially. The other MS drug, Tysabri's sales also declined 8% sequentially.

2017 Guidance: The company said it expects revenues in the range of 11.1 to $11.4 billion. Earnings are expected to be between $20.45 and $21.25.

Pre-Market Trading: Shares were down more than 2% in pre-market trading .

Check back later for our full write up on this BIIB earnings report later!

Zacks' Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BIIB

Other Topics

Earnings Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More